Ask AI
ProCE Banner Activity

Rationale for Using Immunotherapy in the Treatment of ES-SCLC

Slideset Download
Download this brief slideset on the rationale for using immunotherapy in the treatment of ES-SCLC.

Released: December 01, 2020

Expiration: November 30, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania